5news.Canadian news, all in one place

BREAKING

› Industrial Robot Installations Hit Record Highs as Global Labor Shortages Deepen › Trekor Updates Status of Aley Niobium and Strengthens Project Team › U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome › Corpay Cross-Border Named the Official FX Partner of European T20 Premier League › Renewed exploration in Saskatchewan’s Uranium City brings hope to current, former residents › The city gardener: How much rain is too much?› Prospect of Interest: Canadian ‘Tugboat’ Wilkinson pulls into majors with Giants › Former Wimbledon finalist Nick Kyrgios suspended after positive test for cocaine › LILLEY: What did Carney give up to get tentative deal with Trump?› At least 350 aid workers killed in 2025, more than half in Gaza: UN › Industrial Robot Installations Hit Record Highs as Global Labor Shortages Deepen › Trekor Updates Status of Aley Niobium and Strengthens Project Team › U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome › Corpay Cross-Border Named the Official FX Partner of European T20 Premier League › Renewed exploration in Saskatchewan’s Uranium City brings hope to current, former residents › The city gardener: How much rain is too much?› Prospect of Interest: Canadian ‘Tugboat’ Wilkinson pulls into majors with Giants › Former Wimbledon finalist Nick Kyrgios suspended after positive test for cocaine › LILLEY: What did Carney give up to get tentative deal with Trump?› At least 350 aid workers killed in 2025, more than half in Gaza: UN

Latest

Merck, Moderna skin cancer vaccine reduces disease’s recurrence, spread in large trial

The Globe and Mail · August 19, 2026 at 7:18 a.m.

Merck, Moderna skin cancer vaccine reduces disease’s recurrence, spread in large trial

Merck MRK-N and Moderna MRNA-Q said on Wednesday a study of a personalized mRNA vaccine combined with the immunotherapy drug Keytruda reduced skin cancer recurrence and spread compared with Keytruda alone, the first positive late-stage trial results for an mRNA cancer vaccine.

Read the full article on The Globe and Mail ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on www.theglobeandmail.com — the content belongs to The Globe and Mail.

More from The Globe and Mail

Former Meta engineer returns to stand in major trial over social media’s harm to young users

The Globe and Mail · 1 h ago

ICC criticizes latest U.S. sanctions on court’s president and senior prosecution lawyer

The Globe and Mail · 1 h ago

UAE suspends trade with Iran after coming under renewed fire, adding economic pressure

The Globe and Mail · 1 h ago

Can older Canadians afford to leave a marriage? The costs of ‘grey divorce’

The Globe and Mail · 1 h ago

More in Latest

Industrial Robot Installations Hit Record Highs as Global Labor Shortages Deepen

Financial Post · 10 min ago

Trekor Updates Status of Aley Niobium and Strengthens Project Team

Financial Post · 10 min ago

U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome

Financial Post · 10 min ago

Corpay Cross-Border Named the Official FX Partner of European T20 Premier League

Financial Post · 12 min ago

Renewed exploration in Saskatchewan’s Uranium City brings hope to current, former residents

Global News Canada · 15 min ago

The city gardener: How much rain is too much?

Ottawa Citizen · 22 min ago